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EDITORIAL
Regulatory T Cell Defects in Rheumatoid Arthritis
Sujata Sarkar and David A. Fox
Regulatory T (Treg) cells have emerged as a
distinct subset of lymphocytes that are responsible for
limiting immune responses and avoiding pathologic au-
toimmunity. Evidence is accumulating that defects in
Treg function are important in immune-mediated dis-
eases such as rheumatoid arthritis (RA). We discuss
herein the biology of Treg cells and emphasize what is
known about Treg dysfunction in RA.
Treg cells, a component of immune homeostasis
Specific immunologic tolerance to self antigens
requires the immune system to discriminate between self
and nonself. Elimination of self-reactive T cells in the
thymus during T cell development leads to central
tolerance. Peripheral tolerance is designed both to con-
trol responses to foreign antigens encountered in the
periphery and to maintain tolerance to self antigens.
While tolerance is mediated by a variety of mecha-
nisms, work over the last 12 years has established a
critical role for a specific subset of T cells known as
regulatory T cells.
How are Treg cells identified?
Interest in regulatory T cells represents a rein-
carnation of immunologic concepts that were first pro-
posed decades ago. The initial reports of what were then
called T suppressor cells appeared in the 1970s, but
these cells were difficult to characterize, and they fell
out of favor by the late 1980s, despite intriguing evidence
of defective T suppressor cell dysfunction in systemic
rheumatic diseases. Subsequent experiments performed
by Sakaguchi et al (1) reinvigorated interest in what
were renamed regulatory T cells, and focused greater
attention on the regulation of T cell function by a
subset of CD4 cells, in contrast to an earlier focus
on the suppression of antibody production by CD8
suppressor cells. Sakaguchi showed that adoptive trans-
fer of CD4,CD25– T cells into athymic nude mice
resulted in autoimmune disease in the recipient ani-
mals, which was ameliorated by transfer of CD4,
CD25 T cells. CD25, the interleukin-2 receptor
-chain (IL-2R), is also expressed by activated T cells,
but the CD4,CD25high cells among the CD4,CD25
subset are considered to be Treg cells. In general, the
characteristics of mouse and human CD4,CD25
Treg cells are similar. Typically, 8–12% of CD4 T cells
are CD25 Treg cells.
How do Treg cells develop?
Current data suggest that there are 2 subsets of
Treg cells, the CD4,CD25 natural Treg (nTreg) cells,
which mediate central tolerance, and induced Treg
(iTreg) cells, which mediate peripheral tolerance. Natu-
ral Treg cells develop in the thymus, have a repertoire
similar to that of conventional T cells but more skewed
toward recognition of autoantigens, undergo clonal ex-
pansion upon antigen exposure, and yet maintain their
suppressive phenotype. The thymic cellular events un-
derlying the development and maturation of nTreg cells
are not fully understood. It is possible that some thymo-
cytes receive a strong signal via their T cell receptor
(TCR) and CD28, escape negative selection, and differ-
entiate into nTreg cells. The nTreg cells then migrate
to the periphery and suppress autoreactive T cells, thus
suppressing autoimmunity. Stimulation through the
CD28 molecule is also required for the survival and
proliferation of nTreg cells in the periphery. These cells
express CD25, forkhead box P3 (FoxP3)/winged-helix
transcription factor, cytotoxic T lymphocyte–associated
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protein 4 (CTLA-4), and glucocorticoid-induced tumor
necrosis factor receptor (GITR). (GITR is not a true
tumor necrosis factor receptor [TNFR] despite its name,
but rather, it is a member of the TNFR family.) In
addition to nTreg cells, subsets of / T cells and NK1.1
T cells also develop in the thymus that have a suppres-
sive phenotype in the periphery (2).
Induced Treg cells are generated in the periphery
after antigen recognition by CD4,CD25– T cells.
These cells acquire FoxP3 and CD25 expression and
have suppressive functions. The biology of iTreg cells
is complex and less well understood than that of the
nTreg cells. The type and amount of antigen, as well as
the route of antigen administration, can influence the
generation of iTreg cells in the periphery. Intranasal or
oral administration of antigens has been shown to
induce iTreg cells, and they can also be generated by
low-affinity antigen recognition or altered TCR signal-
ing. The repertoire of the iTreg TCR is not known.
Intact CD28 signaling may not be necessary for the
generation of iTreg cells in the periphery. The iTreg
cells are made up of different subsets, each with a
unique cytokine profile or surface phenotype. These
are generated after exposure of naive T cells to antigen
and a variety of other signals, such as IL-10, IL-4,
transforming growth factor  (TGF), vitamin D3, or
plasmacytoid dendritic cells. In addition to CD4 Treg
cells, a subset of mature CD8 T cells has regulatory
function (3).
How do Treg cells function?
Treg cells are anergic and require IL-2 or T cell
receptor ligation for their proliferation and suppres-
sive function. Their effector function is not restricted
by histocompatibility antigens, and they can suppress
both CD4 and CD8 T cells in an antigen-nonspecific
manner (2). Treg cells can selectively suppress various
aspects of T effector function, such as proliferation,
cytokine production, chemokine receptor expression, or
cytolytic function. The precise mechanisms underlying
suppression mediated by Treg cells are controversial. It
is possible that Treg cells suppress immunologic re-
sponses in multiple ways, which may involve contact-
dependent processes, with direct contact between Treg
cells and T effector cells, or may involve Treg interac-
tions with antigen-presenting cells (APCs), which then
suppress T effector cells. Other mechanisms may in-
clude cytotoxic killing of target cells by Treg cells, pro-
duction of suppressive cytokines, or induction of other
regulatory cells.
The contact-dependent suppression is mediated
by the interaction of CTLA-4 on Treg cells with CD80/
CD86 on T effector cells, leading to down-regulation of
T effector function. Alternatively, CTLA-4 on Treg cells
could interact with CD80/CD86 on APCs and induce
indoleamine dioxygenase (IDO) in the APCs. IDO causes
the depletion of tryptophan and the formation of toxic
metabolites, resulting in local suppression of T cell
proliferation. Treg cells can also express granzyme A
and kill T effector cells in a perforin-dependent manner.
IL-10 has immunosuppressive effects in vivo, and both
nTreg and iTreg cells have been shown to mediate
suppression via expression of this cytokine. TGF is
another immunosuppressive cytokine, and studies have
shown that it may be responsible for both the expansion
of Treg cells and Treg cell–mediated suppression of
CD8 T cells. Most of these mechanisms have been
studied in vitro and some of them (e.g., cytotoxic killing)
may not be occurring in vivo. The current notion is
that the nTreg cells mediate suppression via a contact-
dependent mechanism and the iTreg cells mediate
suppression in a contact-independent, cytokine (IL-10
and TGF)–mediated manner (4).
What is FoxP3, and why is it important?
FoxP3, a transcription factor uniquely expressed
by Treg cells, is critically important in the development
of these cells. Humans with defective/mutated FoxP3
develop immune dysregulation, polyendocrinopathy, en-
teropathy, and X-linked syndrome. In addition to FoxP3,
CD28, CD40, and IL-2 are also important in the devel-
opment of Treg cells. IL-2 receptor–knockout mice lack
both nTreg and iTreg cells, implying that IL-2 is abso-
lutely necessary for their development. Treg cells also
express GITR, CTLA-4, CD103, CD62L, OX40L,
TNFRII, TGF receptor type I (TGFRI), 4-1BB,
programmed death 1, neuropilin, and lymphocyte acti-
vation gene 3 (LAG-3). Ligands of some of these
molecules are expressed on APCs (i.e., GITR ligand and
4-1BB ligand). There is some degree of differential
expression of the surface molecules on different subsets
of Treg cells. However, the functional roles of these
surface molecules are yet to be fully understood. All of
these structures are also expressed on conventional
activated T cells except FoxP3, neuropilin, and LAG-3.
LAG-3, a class II major histocompatibility com-
plex (MHC)–binding CD4 analog, is expressed selec-
tively on Treg cells, and antibodies against LAG-3 in-
hibit the suppressive function of these cells.
Neuropilin-1, a receptor involved in axon guidance,
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angiogenesis, and activation of T cells, is constitutively
expressed on CD4,CD25,FoxP3 T cells and is
down-regulated in activated T effector cells (3,5,6).
What do we know about Treg cells in RA?
Few studies have been conducted to evaluate the
role of Treg cells in RA. There is controversy regarding
the relative number of CD4,CD25 T cells in the
peripheral blood of patients with RA. Most studies
concur that there are increased numbers of Treg cells in
RA synovium. CD4,CD25 T cells from the inflamed
joint express higher levels of CTLA-4 and GITR and
have an activated phenotype, which is characterized by
the expression of CD69 and class II MHC molecules.
Thus, there is ongoing inflammation and joint damage in
the presence of increased numbers of CD4,CD25
cells in the RA joint. Studies have shown that
CD4,CD25 Treg cells from patients with RA have a
defective ability to suppress the production of TNF and
interferon- (IFN) by CD4 T cells or monocytes,
even though they can suppress the proliferation of T
effector cells (7,8).
TNF is abundantly present in the sera and joints
of patients with RA. It has been shown that TNF in-
hibits the suppressive function of nTreg cells and
TGF1-induced Treg cells. CD4,CD25 cells express
TNFRII, and signaling through this receptor by TNF
results in decreased FoxP3 expression and an associated
decrease in suppressive function. Treg cells from pa-
tients with active RA have reduced expression of FoxP3
and demonstrate blunted suppression of cytokine pro-
duction and proliferation of T effector cells. In patients
who undergo anti-TNF therapy (infliximab), there is an
increased number of CD4,CD25 T cells, increased
FoxP3 expression, and restoration of the cytokine-
suppressive function of Treg cells (8). Furthermore,
IL-6, which has been shown to be abundantly present
in the rheumatoid synovium, has also been shown to
render T effector cells resistant to Treg-mediated sup-
pression (9).
The role of CD4,CD25 cells in the pathogen-
esis and regulation of arthritis has been best studied in a
mouse model of RA, collagen-induced arthritis (CIA).
Depleting Treg cells with anti-CD25 antibody before
the onset of arthritis has been shown to result in in-
creased cellular and humoral immune responses and
increased arthritis severity (10). Adoptive transfer of
CD4,CD25 T cells was shown to result in decreased
severity of disease (11). These studies suggest that Treg
cells are important in the immune imbalance that cul-
minates in arthritis.
IFN is a Th1 cytokine that has both protective
and deleterious effects in CIA. Experiments have shown
that IFN receptor (IFNR) deficiency did not change
the number or in vitro suppressive function of
CD4,CD25 T cells. However, CD4,CD25 T cells
from IFNR-deficient mice had impaired suppressive
ability in vivo and developed worse arthritis. This was
likely secondary to altered interaction of the Treg cells
with APCs on an IFN-deficient background (12).
In this issue of Arthritis & Rheumatism, van
Amelsfort and colleagues (13) provide additional insight
into how Treg function might be thwarted in RA. They
propose that activated monocytes interacting with Treg
cells through both cell–cell contact and secreted cyto-
kines could prevent Treg cells from executing their
program of immune suppression. Arguing that RA
synovial monocytes overexpress CD80 and CD86, the
ligands for the prototypical T cell costimulatory mole-
cule CD28, these investigators added an agonistic mono-
clonal anti-CD28 to cocultures of Treg cells and their T
effector cell targets and observed a reduction in Treg
function.
Interpretation of this experimental system is
complex, since anti-CD28 could directly affect either the
Treg cells or the target cells and/or alter contact between
the two cell populations. Moreover, the extent to which
anti-CD28 can be used as a proxy for the monocyte cell
surface is a matter of debate. This work is interesting in
the context of the recent clinical introduction of CTLA-
4Ig as a biologic therapeutic for RA. CTLA-4Ig is
believed to reduce the binding of CD28 ligands on
monocytes and other cells to CD28 on T cells. If this
action of CTLA-4 protects Treg function and inhibits T
effector cell activation, a two-pronged beneficial effect
on T cell homeostasis would be achieved. On the other
hand, to the extent that CTLA-4 on Treg cells is
necessary for the suppression of T effector cells through
cell–cell contact between T effectors and Treg cells,
CTLA-4Ig could theoretically interfere with Treg func-
tion. Analysis of the effects of CTLA-4Ig in vivo on the
numbers, activation state, and function of Treg cells in
RA patients would be both feasible and informative.
Other experiments conducted by van Amelsfort
(13) examined the effects of several proinflammatory
cytokines on the function of Treg cells. TNF and espe-
cially IL-7, but not IL-6, inhibited Treg function. These
cytokines are appropriate for study since they are all
present in the RA synovium and are proinflammatory.
As the authors point out, the effect of IL-7 may be to
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render T effector cells resistant to Treg cells, since the
Treg cells themselves show minimal expression of the
IL-7 receptor. The results with TNF provide yet another
possible mechanism for favorable effects of TNF block-
ers in RA.
Their negative findings with IL-6 may require
further experimental investigation with a wider range of
IL-6 concentrations, since the concentrations of IL-6
used in vitro were no higher that the TNF concentra-
tions used in these experiments, while the production
and levels of IL-6 in vivo may be much higher. As noted
in the article (13), IL-6 potently interferes with the
function of mouse Treg cells, and the notion that human
T cells are less responsive to IL-6 seems unconvincing.
The potential importance of IL-6 as a therapeutic target
in RA is further highlighted by the observation that IL-6
plus TGF are critical to the development of the
recently described Th17 subset of CD4 T cells, while
TGF in the absence of IL-6 can both favor the devel-
opment of Treg cells and mediate some of the functions
of Treg cells (14–16). Th17 cells produce IL-17, which
plays a critical role in many immune-mediated diseases
in mouse model systems, and probably in RA as well. It
is likely that these cells, as well as cytokines that promote
their development, will become important targets in the
treatment of RA and other human diseases.
Treg cells, the reincarnation of T suppressor
cells, are here to stay—this time around. The complexity
of the immune system and its regulatory pathways is
daunting, but this should not discourage further at-
tempts at understanding Treg cell function. After all, if
nature has devised exquisite mechanisms for regulating
autoimmunity while simultaneously preserving host de-
fenses, should not our goal in the treatment of auto-
immune disease be the restoration of this balance?
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